The world’s first battery-hybrid self-unloader, recently named M/V Nampu in a ceremony at China’s Jiangjiang Nanyang Shipyard ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Washington: The Trump administration is imposing a 100 per cent tariff on imports of patented drugs, with Australian-made pharmaceuticals subject to the highest possible rate despite carve-outs for ...

Australia’s biggest biotech company CSL said it was assessing the impact of an executive order by US President Donald Trump, with early indications suggesting it would be largely exempt and face ...

BRADLEY, Ill. -- Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Melbourne-based company will ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...